Srinivas Akkaraju - 22 Sep 2025 Form 4 Insider Report for vTv Therapeutics Inc. (VTVT)

Reporting relationship: Director
Issuer ticker: VTVT
Reported as of: 22 Sep 2025
Net transaction value: +$1,618,090
SEC form: 4
Accepted by SEC: 25 Sep 2025, 17:04:22 UTC
Prior SEC filing: 08 Sep 2025
Next SEC filing: 07 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Srinivas Akkaraju

Key filing fact

Srinivas Akkaraju filed Form 4 for vTv Therapeutics Inc. (VTVT) on 25 Sep 2025.

Key facts

This page summarizes Srinivas Akkaraju's Form 4 filing for vTv Therapeutics Inc. (VTVT).
3 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 25 Sep 2025, 17:04.

Change

Previous filing in this sequence was filed on 08 Sep 2025.
Current net transaction value: +$1,618,090.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001253170 Primary reporting owner

AKKARAJU SRINIVAS

Relationship: Director
Address: C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT
Signature: /s/ Srinivas Akkaraju
Signature date: 24 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VTVT transaction

Class A Common Stock

Award

Transaction value: $1,618,090
Shares: +106,000
Change %
Price: $15.26
Shares after: 106,000
Date: 22 Sep 2025
Ownership: By Samsara Opportunity Fund, L.P.
Footnotes: F1, F2

VTVT holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 206,784
Date: 22 Sep 2025
Ownership: By Samsara BioCapital, L.P.
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VTVT transaction Derivative

Pre-Funded Warrants (Right to Buy)

Award

Transaction value
Shares: +877,214
Change %
Price
Shares after: 877,214
Date: 22 Sep 2025
Ownership: By Samsara Opportunity Fund, L.P.
Underlying class: Class A Common Stock
Underlying amount: 877,214
Exercise price: $0.0100
Footnotes: F1, F2, F4

VTVT transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +983,214
Change %
Price
Shares after: 983,214
Date: 22 Sep 2025
Ownership: By Samsara Opportunity Fund, L.P.
Underlying class: Class A Common Stock
Underlying amount: 983,214
Exercise price: $22.71
Footnotes: F1, F2, F5

VTVT holding Derivative

Pre-Funded Warrants (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,548,101
Date: 22 Sep 2025
Ownership: By Samsara BioCapital, L.P.
Underlying class: Class A Common Stock
Underlying amount: 1,548,101
Exercise price: $0.0100
Footnotes: F3, F4

VTVT holding Derivative

Warrant (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 655,523
Date: 22 Sep 2025
Ownership: By Samsara BioCapital, L.P
Underlying class: Class A Common Stock
Underlying amount: 655,523
Exercise price: $22.71
Footnotes: F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

On August 29, 2025, Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025.

Footnote F2

Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

Footnote F3

These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

Footnote F4

The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.

Footnote F5

The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met. A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.